Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
TipRanksApr 30 03:31 ET
Aldeyra Therapeutics Unveils R&D Progress and Goals
TipRanksApr 25 07:13 ET
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
BusinesswireApr 25 07:00 ET
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
PDF Version LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the tr
Aldeyra TherapeuticsApr 18 00:00 ET
Aldeyra Therapeutics(ALDX.US) 10% Shareholder Buys US$833.87K in Common Stock
$Aldeyra Therapeutics(ALDX.US)$ 10% Shareholder PERCEPTIVE ADVISORS LLC purchased 177.99K shares of common stock on Apr 4, 5, 2024 at an average price of $4.68 for a total value of $833.87K. This tran
moomoo NewsApr 8 18:12 ET
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Aldeyra Therapeutics’ALDX clinical-stage immunology pipeline comprises two candidates, reproxalap and ADX-629, which are undergoing late-stage and mid-stage development, respectively.
Yahoo FinanceApr 6 06:37 ET
Aldeyra Gains as Perceptive Advisors Boosts Stake
Seeking AlphaApr 4 10:16 ET
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders inte
BenzingaApr 4 06:23 ET
Aldeyra Therapeutics(ALDX.US) 10% Shareholder Buys US$1.93 Million in Common Stock
$Aldeyra Therapeutics(ALDX.US)$ 10% Shareholder PERCEPTIVE ADVISORS LLC purchased 504.27K shares of Common Stock on Apr 1, 2, 3, 2024 at an average price of $3.84 for a total value of $1.93 million. T
moomoo NewsApr 3 18:02 ET
Aldeyra's Dry Eye Disease Drug May Be On Path For FDA Approval -- Market Talk
1438 ET - Aldeyra Therapeutics surges 15% to $4.10, following an upgrade from Oppenheimer citing the company's development plan for resubmitting a New Drug Application [NDA] for its dry eye disease tr
WSJApr 3 14:38 ET
Express News | Aldeyra Therapeutics Shares Are Trading Higher After Oppenheimer Upgraded the Stock From Perform to Outperform and Announced a $10 Price Target
Moomoo 24/7Apr 3 12:02 ET
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target
Aldeyra Therapeutics (ALDX) has an average rating of Buy and price targets ranging from $7 to $11, according to analysts polled by Capital IQ. Price: 3.7, Change: +0.15, Percent Change: +4.22
MT NewswiresApr 3 09:04 ET
Aldeyra Gains as Oppenheimer Upgrades on Revised Plans for Lead Asset
Seeking AlphaApr 3 09:01 ET
Express News | HC Wainwright & Co. Reinstates Buy on Aldeyra Therapeutics, Announces $10 Price Target
Moomoo 24/7Apr 2 08:43 ET
Aldeyra Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 205.81% HC Wainwright & Co. → $10 Reinstates Buy → Buy 10/17/2023 144.65% Citigroup $25 → $8 Ma
BenzingaApr 2 08:42 ET
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)
TipRanksApr 2 06:20 ET
Aldeyra Gains on Plans for AbbVie-partnered Eye Disease Drug
Seeking AlphaMar 28 13:42 ET
Express News | Aldeyra Therapeutics Shares Are Trading Higher. The Company Announced the Clinical Development Plan Intended to Enable Resubmission of a New Drug Application for Reproxalap in Dry Eye Disease
Moomoo 24/7Mar 28 12:02 ET
Express News | Aldeyra Therapeutics Disclosed Clinical Development Plan For Resubmission Of New Drug Application For Reproxalap In Dry Eye Disease
Moomoo 24/7Mar 28 07:14 ET
Aldeyra Therapeutics Unveils Reproxalap Development Update
TipRanksMar 28 07:12 ET
No Data
No Data